Marketing application of BOGUTAI® (teriparatide injection) has been officially accepted by the China National Medical Products Administration (NMPA)
- Written by Viw Magazine
HONG KONG SAR - EQS Newswire - 29 June 2022 - A fully integrated biopharmaceutical company – Uni-Bio Science Group Limited (the "Company", together with its subsidiaries, the "Group"; Stock code: 00690.HK) is pleased to announce that t the marketing application submitted by the Group's self-developed BOGUTAI® (teriparatide injection) has been accepted by the China National Medical Products Administration ("NMPA") on 28 June 2022, with the acceptance number "CXSS2200062国".
